MDRO Susceptibility Testing by Broth Microdilution
Confidently identify accurate antibiotic MICs for MDRO with broth microdilution
The need for clinicians to turn to last-resort antibiotics, such as colistin, to tackle multi-drug resistant organisms (MDRO) is increasing. Accurate antimicrobial susceptibility testing (AST) is essential to support careful antibiotic stewardship to ensure the right antibiotic is prescribed at the right dose for the right duration in order to deliver the best patient outcomes, and to preserve effectiveness.
Having confidence in your AST method and access to test the latest drug combinations is critical but can be a challenge. Obtaining a true MIC by broth microdilution offers a reliable solution.
EUCAST recommends broth microdilution as the only valid method for colistin
Recognising that antimicrobial susceptibility testing of colistin has been ‘fraught with difficulties’ a joint EUCAST and CLSI subcommittee has recommended that broth microdilution (BMD) is so far the only valid method.1 EUCAST has also issued warnings regarding some AST methods for piperacillin-tazobactam, antibiotics that are potential alternative treatments for MDROs.
Ensure accurate colistin dosing with MIC results by broth microdilution
Matuschek et al., EUCAST Development Laboratory, Sweden, evaluated five commercial MIC methods for colistin antimicrobial susceptibility testing for Gram negative bacteria and recommend broth microdilution for MIC determination.
Antibiotic resistance facts and stats
Up to 50% of the time, antibiotics are not optimally prescribed.3 Being aware of antibiotic resistance patterns within facilities and leading programs to improve prescribing practices is essential.
Utilizing the Sensititre system to face the challenge of Gram negative MDRO susceptibility testing
Dr Decousser, from the microbiology laboratory of Henri Mondor Hospital, France, explains how implementing the Thermo Scientific™ Sensititre™ broth microdilution system achieved time savings in reporting results, as well as providing clinicians with accurate and extensive evaluation of minimum inhibitory concentrations (MICs) and alternative therapeutic options.
“We are so pleased with our Gram negative plate that we may now consider a plate for Gram positive organisms," concludes Dr. Decousser.
Thermo Fisher Scientific provided a custom-designed broth microdilution plate with the exact combination and dilution of antibiotics required by the laboratory, in a timely manner.
Tailor-made antimicrobial susceptibility testing with the latest antimicrobials
Through Thermo Fisher Scientific's collaboration with many pharmaceutical companies, the Sensititre system gives you access to the latest antimicrobials to design a Sensititre custom plate tailored to your formulary, dilution ranges and patient population. With the ability to update formats conveniently, you get relevant results that are based on real-time resistance trends and local epidemiology, allowing you to improve clinical success and effectively manage resistance in your institution.
Access the latest antimicrobials, including Ceftazidime/Avibactam and Ceftolozane/Tazobactam, and learn more about our custom-designed Sensititre plates.
Discover the accuracy of a true MIC with the Sensititre system and workflow
Not all products are available in all countries. Please inquire.
New antimicrobial resistance webinar library
Learn about antimicrobial stewardship straight from the industry experts. Watch our series of educational webinars covering advances in blood culture, susceptibility testing, sepsis, antimicrobial stewardship, and antimicrobial resistance.
- European Committee of Antimicrobial Susceptibility testing: EUCAST warnings concerning antimicrobial susceptibility testing products or procedures http://www.eucast.org/ast_of_bacteria/warnings/ [Accessed May 2018]
- Matuschek, E. et al. (2017) Clinical Microbiology and Infection. Antimicrobial susceptibility testing of colistin e evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter spp. https://doi.org/10.1016/j.cmi.2017.11.020